Invention Grant
- Patent Title: Heteroaromatic NMDA receptor modulators and uses thereof
-
Application No.: US16779517Application Date: 2020-01-31
-
Publication No.: US11236104B2Publication Date: 2022-02-01
- Inventor: David R. Anderson , Robert A. Volkmann , Frank S. Menniti , Christopher Fanger
- Applicant: Cadent Therapeutics, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Cadent Therapeutics, Inc.
- Current Assignee: Cadent Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Steven G. Davis; Michael J. DeGrazia
- Main IPC: C07D495/04
- IPC: C07D495/04 ; C07D471/04 ; C07D493/04 ; C07D498/04 ; C07D513/04 ; C07D487/04 ; C07D217/24 ; C07D239/90 ; C07D401/06 ; C07D403/06 ; C07F7/08 ; A61K31/519 ; A61K31/397
Abstract:
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
Public/Granted literature
- US20210107916A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF Public/Granted day:2021-04-15
Information query
